BRPI0607507A2 - método in vitro para a identificação de compostos para tratamento do cáncer - Google Patents

método in vitro para a identificação de compostos para tratamento do cáncer

Info

Publication number
BRPI0607507A2
BRPI0607507A2 BRPI0607507-0A BRPI0607507A BRPI0607507A2 BR PI0607507 A2 BRPI0607507 A2 BR PI0607507A2 BR PI0607507 A BRPI0607507 A BR PI0607507A BR PI0607507 A2 BRPI0607507 A2 BR PI0607507A2
Authority
BR
Brazil
Prior art keywords
cancer
individual
vitro method
identification
cancer treatment
Prior art date
Application number
BRPI0607507-0A
Other languages
English (en)
Inventor
Sanjuan Juan Carlos Lacal
De Molina Ana Ramirez
Ortega David Gallego
Coronel Monica Banez
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of BRPI0607507A2 publication Critical patent/BRPI0607507A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MéTODO IN VITRO PARA A IDENTIFICAçãO DE COMPOSTOS PARA TRATAMENTO DO CáNCER. A presente invenção está relacionada a um método in vitro para identificação e avaliação de compostos úteis no tratamento de diferentes tipos de cãncer, especialmente câncer de pulmão, de mama, colo-retal e de bexiga em um indivíduo, para a determinação do estágio ou da gravidade do referido câncer no indivíduo ou para o monitoramento do efeito do tratamento administrado a um indivíduo que apresenta o referido câncer; à verificação, identificação, desenvolvimento e avaliação da eficácia de compostos para o tratamento do referido câncer, com a finalidade de desenvolver novos produtos medicinais; bem como aos agentes que inibem a expressão e/ou a atividade da proteína colina quinase alfa e/ou os efeitos dessa expressao.
BRPI0607507-0A 2005-04-13 2006-04-12 método in vitro para a identificação de compostos para tratamento do cáncer BRPI0607507A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200500875 2005-04-13
PCT/ES2006/070047 WO2006108905A1 (es) 2005-04-13 2006-04-12 Método in vitro para identificar compuestos para terapia del cáncer

Publications (1)

Publication Number Publication Date
BRPI0607507A2 true BRPI0607507A2 (pt) 2009-09-08

Family

ID=37087793

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607507-0A BRPI0607507A2 (pt) 2005-04-13 2006-04-12 método in vitro para a identificação de compostos para tratamento do cáncer

Country Status (16)

Country Link
US (3) US8481256B2 (pt)
EP (2) EP2246441B1 (pt)
JP (1) JP4759612B2 (pt)
KR (3) KR101352142B1 (pt)
CN (3) CN103215351A (pt)
AT (1) ATE454465T1 (pt)
BR (1) BRPI0607507A2 (pt)
CA (1) CA2604803A1 (pt)
DE (1) DE602006011607D1 (pt)
DK (1) DK1889920T3 (pt)
ES (1) ES2341729T3 (pt)
MX (1) MX2007012668A (pt)
PL (1) PL1889920T3 (pt)
PT (1) PT1889920E (pt)
RU (1) RU2434946C2 (pt)
WO (1) WO2006108905A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025686A4 (en) 2006-05-29 2009-12-23 Consejo Superior Investigacion ANTI-CHOLINE KINASE ALPHA MONOCLONAL ANTIBODIES AND THEIR APPLICATION IN CANCER DIAGNOSTIC ANALYSIS, ANALYSIS AND DRUG PREPARATION TECHNIQUES
WO2009126764A1 (en) 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
WO2010001369A2 (es) * 2008-07-04 2010-01-07 Translational Cancer Drugs Pharma, S.L. Métodos para el tratamiento y diagnóstico del cáncer
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
AU2012274156A1 (en) * 2011-06-20 2014-01-23 Traslational Cancer Drugs Pharma, S.L. Method for predicting the clinical response to chemotherapy in a subject with cancer
JP2013230145A (ja) * 2012-04-30 2013-11-14 Masahiko Sato 細胞集団の状態を評価するための方法、候補化合物の発癌性を評価するための方法、潜在的な抗癌化合物の抗癌活性を評価するための方法及び治療用細胞集団の品質を評価するための方法
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2015028662A1 (en) * 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
RU2552305C1 (ru) * 2014-04-04 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт физиологии природных адаптаций Уральского отделения Российской академии наук Способ прогнозирования риска развития злокачественных новообразований
KR20180069839A (ko) 2015-10-08 2018-06-25 자임워크스 인코포레이티드 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
RU2657417C1 (ru) * 2017-05-29 2018-06-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования риска озлокачествления узловых образований у больных с эндокринологическими заболеваниями
RU2713795C1 (ru) * 2019-06-13 2020-02-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования возможности озлокачествления опухоли яичника у женщин репродуктивного возраста
CN117849343A (zh) * 2021-05-31 2024-04-09 浙江大学 基于CHKα的非代谢功能作为癌症治疗、诊断和预后预测之靶标的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1994000603A1 (en) 1992-06-26 1994-01-06 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
JPH05243020A (ja) * 1992-03-02 1993-09-21 Rohm Co Ltd チップネットワーク型抵抗器
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP3756612B2 (ja) * 1997-03-18 2006-03-15 ローム株式会社 チップ型抵抗器の構造及びその製造方法
WO1999001876A1 (fr) * 1997-07-03 1999-01-14 Matsushita Electric Industrial Co., Ltd. Resistance et procede de fabrication
US20030077568A1 (en) 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
JP4078042B2 (ja) * 2001-06-12 2008-04-23 ローム株式会社 複数の素子を有するチップ型電子部品の製造方法
JP3846312B2 (ja) * 2002-01-15 2006-11-15 松下電器産業株式会社 多連チップ抵抗器の製造方法
US20030186241A1 (en) 2002-03-20 2003-10-02 Ken-Shwo Dai Human choline/ethanolamine kinase (HCEK)-related gene variant associated with lung cancers
US20040115656A1 (en) * 2002-12-16 2004-06-17 Tai-Jay Chang Treating breast cancer
JPWO2005001089A1 (ja) * 2003-06-27 2006-11-02 生化学工業株式会社 癌の検出方法
JP2005073548A (ja) * 2003-08-29 2005-03-24 National Cancer Center-Japan 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、ＨＮＦ−１βの利用
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.

Also Published As

Publication number Publication date
EP2246441B1 (en) 2015-12-16
EP1889920A1 (en) 2008-02-20
DK1889920T3 (da) 2010-05-10
KR101322705B1 (ko) 2013-10-29
ES2341729T3 (es) 2010-06-25
ATE454465T1 (de) 2010-01-15
KR20080080430A (ko) 2008-09-04
PL1889920T3 (pl) 2010-06-30
US20140023657A1 (en) 2014-01-23
CN103215351A (zh) 2013-07-24
US8901096B2 (en) 2014-12-02
JP4759612B2 (ja) 2011-08-31
EP2246441A1 (en) 2010-11-03
RU2434946C2 (ru) 2011-11-27
RU2007141930A (ru) 2009-05-20
US8481256B2 (en) 2013-07-09
EP1889920B1 (en) 2010-01-06
CN102228689A (zh) 2011-11-02
MX2007012668A (es) 2008-03-11
CA2604803A1 (en) 2006-10-19
KR20130086060A (ko) 2013-07-30
JP2008535511A (ja) 2008-09-04
CN101405403A (zh) 2009-04-08
CN101405403B (zh) 2013-07-10
DE602006011607D1 (de) 2010-02-25
KR20130006703A (ko) 2013-01-17
US20110269948A1 (en) 2011-11-03
KR101352142B1 (ko) 2014-02-17
US20090304575A1 (en) 2009-12-10
PT1889920E (pt) 2010-04-14
WO2006108905A1 (es) 2006-10-19

Similar Documents

Publication Publication Date Title
BRPI0607507A2 (pt) método in vitro para a identificação de compostos para tratamento do cáncer
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
MX2011006091A (es) Inhibidores de imidazopirazina syk.
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
ATE513562T1 (de) Nicht-spezifische immunstimulierende mittel
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]